Novel Therapeutics and Drug Targets 2

• 3073 · PDF Dickkopf1 as a potential therapeutic target in highly aggressive breast cancers Mohd Mughees, Jian Wang, Wendy A. Woodward, Megumi Kai, MDACC IBC Team, Sharon H. Giordano, Chandra Bartholomeusz
• 3074 · PDF A first-in-class ER stress modulator selectively induces regulated cell death of STK11/TP53-deficient cancer cells Ying-Jie Wang, Xiaobing Zhang, Wei Jia, Bo Kang, Zhao Xu, Mingxing Yin, Hongban Zhong
• 3075 · PDF FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma Nakul M. Shah, Beatriz Alvarado-Hernandez, Xinyue Chen, Quentin Kimana, Felicity Namayanja, Wei Lu, Khaja B Khan, Juan Gallegos, Sangeeta Goswami, Lawrence N. Kwong, Luisa M. Solis Soto, Milind M. Javle, Sachet A. Shukla
• 3076 · PDF Development of a SIX1-specific PROTAC for the treatment of esophageal adenocarcinoma Asad Faili, Vic Scharfenberger, Ellen Weber, Samaneh Heydarzadeh, Reinhard Buettner, Tristan Lerbs
• 3077 · PDF A novel MMP-targeting peptide suppresses glioblastoma metastasis by reducing MSI1 activity Xian Liu, Liang-Ting Lin
• 3078 · PDF Targeting the non-canonical neddylation of TGRBR2 suppresses the metastatic potentials of oral squamous cell carcinoma Yuan-Feng Lin
• 3079 · PDF Discovery of a novel, covalent and heterobifunctional thioredoxin reductase inhibitor with antitumor activity Yanyan Han, Nicholas Blazanin, Sasi Kotagiri, Md Qudratullah, Xiaobing Liang, Yonathan Lissanu
• 3080 · PDF Site-specific conjugation of CPL976H-MMAE enables stable and selective dual targeting of PD-L1 and AXL Delfina Popiel, Filip Mitula, Anna Jablonska, Krzysztof Lacek, Natalia Czerwinska, Tomasz Kornatowski, Magdalena Langowska, Sylwia Wieczorek, Bartosz Wiernicki, Damian Kolakowski, Adam Zmyslowski, Tomasz Banach, Joanna Deshayes, Michal Mroczkiewicz, Marcin Zagozda, Joanna Hucz-Kalitowska, Emilia Mroz, Malgorzata Choros, Maciej Wieczorek, Olga Abramczyk
• 3081 · PDF TEAD inhibition by IAG933 as a novel therapeutic strategy for cholangiocarcinoma Hidemi Nishi, Erik Jessen, Danielle M. Carlson, Amro M. Abdelrahman, Enis H. Ozmert, J. Pedro Fincatto Safi, Brandon A. Wilbanks, Shelby K. Yee, Jack W. Sample, Nathan W. Werneburg, Rory L. Smoot
• 3082 A novel iNOS inhibitor as a targeted therapeutic approach for inflammatory breast cancer Karina Ortega Martinez, Maria Florencia Chervo, Feng Li, Jenying Deng, Liliana Guzman-Rojas, Wei Qian, Jianying Zhou, Recep Bayraktar, Aireana Phillips, Ivonne Uzair, Mailin Li, Aijun Zhang, Spencer Hankins, Dale Hamilton, Zhonglin Liu, Christopher Lincoln, Christoforos Thomas, Jenny C. Chang
• 3083 · PDF YT-DP: A glyco-conjugation-based dual-payloads ADC platform Yi Yang, Zhentao Song, Rui Yu, Jiangping Hu, Zhouyang Qian, Xinyue He, Guoli Yang, Ji Chen, Juntao Yu
• 3084 · PDF Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming Yining Chen, Alvaro Curiel-Garcia, Alex Piacentini, Zhouzerui Liu, Tim Olsen, Richard Yau, Praveer Sharma, Liz Murray, Gaetano Viscido, Ken Olive, Andrea Califano
• 3085 · PDF Molecular characterization of inhibition of the DNA repair protein RAD51 by the small molecule JKYN-1 Peter Ferguson, Mark Vincent, Yousef Najajreh, Morgan Black, Sweta Sharma Saha, Melissa Thomas, Olivier Lord, Stephen Ritter, Jean-Yves Masson, Brian Shilton, James Koropatnick
• 3086 · PDF ART1 as an immune modulating therapeutic target in EGFR-mutated lung cancer Mimansa ., Rajika Jindani, Mukherjee Sumit, Jorge Quintero, Naresh Regmi, Grace Ha, Justin Olivera, Justin Rosario, Melissa Tracy, Brendan Mullaley, Victor Gray, Erik Wennerberg, Lindsay M. LaFave, Brendon Stiles
• 3087 · PDF Targeting AURKA and TRIP13 exploits mitotic vulnerability and enhances antitumor immunity in Rb-deficient immunocompetent lung cancer models Soma Ghosh, Jennifer L. Anderson, Andrew G. Sikora, Faye M. Johnson
• 3088 · PDF Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC) Brian McEllin, Gaelle Mercenne, Daniele Canzani, Gavin Hirst, Lindsay Pino, Alexander Joel Federation
• 3089 · PDF Characterization of a novel inhibitor of asparagine synthetase that activates the integrated stress response Nicholas T. Walda, Lucciano A. Pearce, Nigel Richards, Wen Zhu, Yuichiro Takagi, Ronald C. Wek, Kirk A. Staschke
• 3090 · PDF VRK1 inhibition leverages paralog synthetic lethality to selectively target VRK2-deficient cancer cells Kiera M. Vassallo, Kevin M. Cottrell, Katarzyna B. Handing, Mu-Sen Liu, Alvin Lu, Alice Tsai, Maria Dam Ferdinez, Patrick McCarren, Sirimas Sudsakorn, Jannik N. Andersen, Kimberly J. Briggs
• 3091 · PDF Exploring the anti-tumor potential of HLA-G-targeted therapeutics through diverse preclinical approaches Hyeonju Kang, Inyoung Lee, Sungyeon Park, Yoo jin Kim, Kyueun Cho, Hongjai Lee, Yiyoung Choi, Jiyeon Hong, Chihye Park, Chungmin Lee, Gyongsik Ha
• 3092 · PDF Epiregulin and amphiregulin as dual targets in colorectal cancer Cara Biddle-Guernsey, Joan Jacob, Zhengdong Liang, Kendra S. Carmon
• 3093 · PDF SLC25A28 is a synthetic lethal target in nucleotide excision repair-deficient cancer Nan Yang, Vijai Joseph, Lisa Hoeg, Xuechun Bai, Sizhi Gao, Ouathek Ouerfelli, David B. Solit, Jian Carrot-Zhang, Gopa Iyer, Daniel Durocher, Kent W. Mouw, Kenneth Offit, Steven M. Lipkin
• 3094 · PDF Targeting TUBB2B: Exploiting brain metastatic vulnerabilities in triple-negative breast cancer Qingling He, Jianyang Hu, Gary M. Tse, Julia Y. Tsang, Pui-Chi Lo, C Geoffrey Lau, Y Rebecca Chin
• 3095 · PDF Optimizing targeting molecule density on drug carriers to improve cellular uptake Maria Lambros, Manjot Kaur
• 3096 · PDF The anti-cancer effects of silibinin through the modulation of JAK1/STAT3 signaling and inhibition of MMPs levels in triple-negative breast cancer cells Shubham D. Mishra, Patricia Mendonca, Sukhmandeep Kaur, Karam F. a. Soliman
• 3097 Preclinical characterization of MBS309, a PD-1-targeted and alpha-biased IL-2, demonstrating robust anti-tumor activity and a favorable safety profile Jiangmei Li, Guangzhong Lin, Lunfeng Zhang, Shuo Huang, Shuang Qing, Feng Li, Mingze Sun, Hong Chen
• 3098 · PDF Discovery of the RAD51 inhibitor JKYN-1 and characterization of its anticancer activity in preclinical models of non-small cell lung cancer Yifan Yu, Morgan Black, Nikolina Radulovich, Peter Ferguson, James Koropatnick, Ming Sound Tsao, Mark D. Vincent, Geoffrey Liu, Samir H. Barghout
• 3099 · PDF Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysis Ophelia Maertens, Bradley French, Eric Fang, Imad Hanna, Ying Huang, Sajan Joseph, Fallon Lin, Neil Umbreit, Anna Uvarova, Vivek Rauniyar, Samuel Ho

在完整检索应用中浏览本分会场 →